Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Maureen Riordan

Senior Deals Analyst

Connecticut, US
Maureen has been with Strategic Transactions for 20 years, first as a Research Analyst, now as a Senior Deals Analyst, with a brief in-between stint as Editor/Contributor for Start-Up company profiles. In her current role, she primarily researches, analyzes, writes, and edits summaries involving current biopharma and medtech deals – which appear in the ST database and the monthly dealmaking section of In Vivo – and also writes and updates legacy deals. Maureen regularly co-authors a quarterly statistics column covering deal trends in both the biopharma and medtech industries for In Vivo. Prior to joining Strategic Transactions, Maureen was a corporate librarian in a management consulting firm fielding search requests for in-house analysts, and then spent two years with Lexis-Nexis as a customer consultant having daily contact with client subscribers to teach database searching techniques. Maureen holds a Bachelor of Arts degree in English from Niagara University, and a Master of Library Science degree from Southern Connecticut State University.
Advertisement
Set Alert for Articles By Maureen Riordan

Latest From Maureen Riordan

Biopharma Quarterly Dealmaking Statistics, Q4 2016

Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.

BioPharmaceutical Deals

Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

Aduro Biotech discusses what it looks for in an academic collaboration. Plus, Sarepta adds gene therapies to its Duchenne pipeline from Nationwide Children's Hospital and Columbia University out-licenses IP to a pair of biotechs.

Deals StartUps and SMEs

Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick

Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.

StartUps and SMEs Financing

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical

Tech Transfer Roundup: J&J Innovation’s Agnostic Approach To Academic Collaboration

J&J’s Robert Urban explains how his organization’s efforts lead to partnerships with academia across a broad range of areas, including pharmaceuticals, medical devices and consumer products. Also, transactions occurring between Nov. 21 and Dec. 21, including the expansion and solidification of Editas Medicine’s IP estate in CRISPR technology.

Deals StartUps and SMEs

Venture Funding Deals: Stem Cell Venture BlueRock Launches With Major Funding

With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.

Deals Financing
See All
Advertisement
UsernamePublicRestriction

Register